The trial enrolled 1,841 patients and measured DFS, with safety, OS, and quality of life as secondary endpoints.

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the Committee for Medicinal Products for Human Use (CHMP) of the European ...

RAHWAY, N.J.,--(BUSINESS WIRE)-- Merck (MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 LITESPARK-022 trial in patients with clear ...

Late-breaking KEYNOTE-B15 data show KEYTRUDA ® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) significantly improved event-free survival, overall survival and pathologic complete response ...

Patients with clear cell renal cell carcinoma had improved overall survival when treated with adjuvant Keytruda compared to placebo. Patients with clear cell renal cell carcinoma (ccRCC) experienced ...

For decades, researchers have been seeking a therapy to improve outcomes for patients with clear cell renal cell carcinoma who underwent a nephrectomy. Postsurgical immunotherapy significantly ...

As Merck looks for growth opportunities ahead of Keytruda’s tumble over the patent cliff, the company’s future now looks a bit brighter in the glow of two late-stage trial wins for cancer drug Welireg ...

Merck's Keytruda demonstrates superior overall survival with adjuvant therapy compared to placebo in kidney cancer patients. Merck's KEYNOTE-564 trial is the first Phase 3 adjuvant trial to show ...

Keytruda works by inhibiting the activity of the programmed cell death protein 1 (PD-1), which typically limits the activity of your immune system. Cancer cells often produce PD-1 to prevent your ...